306936-02-7 Usage
Properties
It is a chlorinated acyl chloride derivative.
Contains a trifluoromethoxy group on the phenyl ring.
Common Uses
Used in organic synthesis as a building block for various pharmaceuticals, agrochemicals, and materials.
Acts as a reagent in the synthesis of fluorinated organic compounds.
Specific Content
Contains a phenyl group substituted with a trifluoromethoxy group at the 4-position.
Has a prop-2-enoyl chloride functional group at the 3-position.
Unique Properties
The trifluoromethoxy group introduces unique electronic and steric properties.
Useful in developing new chemical entities with improved pharmacological and physical properties.
Safety Considerations
Due to its reactivity and potential hazards, it should be handled with caution.
Follow established safety protocols when working with this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 306936-02-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,6,9,3 and 6 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 306936-02:
(8*3)+(7*0)+(6*6)+(5*9)+(4*3)+(3*6)+(2*0)+(1*2)=137
137 % 10 = 7
So 306936-02-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H6ClF3O2/c11-9(15)6-3-7-1-4-8(5-2-7)16-10(12,13)14/h1-6H/b6-3+
306936-02-7Relevant articles and documents
Prodrugs of N-dicarboximide derivatives of the rat selective toxicant norbormide
Rennison, David,Laita, Olivia,Conole, Daniel,Jay-Smith, Morgan,Knauf, Jan,Bova, Sergio,Cavalli, Maurizio,Hopkins, Brian,Linthicum, Darwin S.,Brimble, Margaret A.
supporting information, p. 5886 - 5899 (2013/09/12)
Norbormide [5-(α-hydroxy-α-2-pyridylbenzyl)-7-(α-2- pyridylbenzylidene)-5-norbornene-2,3-dicarboximide] (NRB), an existing but infrequently used rodenticide, is known to be uniquely toxic to rats but relatively harmless to other rodents and mammals. However, one major drawback of NRB as a viable rodenticide relates to an evolutionary aversion developed by the rat leading to sub-lethal dosing due to either its unpleasant 'taste' or rapid onset of effects. A series of NRB-derived prodrugs were prepared in an effort to 'mask' this acute response. Their synthesis and biological evaluation (in vitro vasoconstrictory activity, in vitro hydrolytic and enzymatic stability and lethality/palatability in vivo) is described. Prodrug 2 displayed the most promising profile with respect to a delay in the onset of symptoms and was subsequently demonstrated to be significantly more palatable to rats. Moreover, prodrug 25 was found to be largely accepted by rats in a choice trial, resulting in high mortality.